Secondly, the introduction of the association of BRAF and MEK inhibitors—two targeted therapies—in clinical practice has changed the therapeutic scenario for advanced melanoma patients harboring BRAF V600 activating mutations, which confer poorer prognoses compared to those with BRAF V600 wild-type status [3]. The gene discussed is BRAF; the disease is melanoma.